Should patients receive thrombophilia testing in the setting of a provoked VTE secondary to hormonal therapy/OCPs?

Topics: Pediatric Oncology • Medical Oncology • Thrombosis • Hematology • Benign Hematology • Hemostasis/Thrombosis

While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?

Answer from: at Academic Institution

Given that oral contraceptives are considered a provoking event (Ortel et al., PMID 33007077), ASH Choosing Wisely guidelines recommend against thrombophilia testing since the recommended duration of anticoagulation is only 3 months. (Hicks et al., PMID 24307720 & Hicks et al., PMID 25472968).

Comments

Medical Oncologist at Locum Tenens
The danger is that many "providers" think that the...

Answer from: Medical Oncologist at Academic Institution

Thrombophilia associated with oral contraceptives is often the event that reveals an underlying thrombophilia, particularly Factor V Leiden. The most common population are young women who will be facing future potential thrombophilic risk, particularly pregnancy. It is more an issue for the future r...

Related Questions